

# MARKET REPORT



Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk)

# Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

## Summary

Global Markets Direct's, 'Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Note:

\*Certain sections in the report may be removed or altered based on the availability and relevance of data.

\*Updated report will be delivered in 48 hours of order confirmation.

## Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)

- The report reviews Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Additional Details

**Publisher :** Global Markets Direct

**Reference :** GMDHC0612TDB

**Number of Pages :** 144

**Report Format :** PDF

**Publisher Information :**



**Global Markets Direct**  
The home of leading edge research and analysis

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

- Table of ContentsTable of Contents 2List of Tables 5List of Figures 6Introduction 7Global Markets Direct Report Coverage 7Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Overview 8Therapeutics Development 9Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Stage of Development 9Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Therapy Area 10Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Indication 11Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Products Glance 13Late Stage Products 13Early Stage Products 14Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Companies 15Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Universities/Institutes 23Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Therapeutics Assessment 25Assessment by Monotherapy/Combination Products 25Assessment by Mechanism of Action 26Assessment by Route of Administration 27Assessment by Molecule Type 28Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 30AbbVie Inc 30ACEA Biosciences, Inc. 32Advinus Therapeutics Ltd 33ArQule, Inc. 34BeiGene, Ltd. 35Beijing Hanmi Pharmaceutical Co Ltd 36Biogen Inc 37Bristol-Myers Squibb Company 38Celgene Corporation 39CrystalGenomics, Inc. 40Genentech, Inc. 41Hanmi Pharmaceuticals, Co. Ltd. 42LSK BioPartners, Inc. 43Merck KGaA 44Ono Pharmaceutical Co., Ltd. 45Pharmacyclics, Inc. 46Principia Biopharma Inc. 47Redx Pharma Plc 48Simcere Pharmaceutical Group 49Sunesis Pharmaceuticals, Inc. 50Takeda Pharmaceutical Company Limited 51Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Drug Profiles 52ABBV-599 - Drug Profile 52AC-058 - Drug Profile 53acalabrutinib - Drug Profile 54Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile 57ARQ-531 - Drug Profile 58BGB-3111 - Drug Profile 59BIIB-068 - Drug Profile 62BMS-986142 - Drug Profile 63BMS-986195 - Drug Profile 64CG-026806 - Drug Profile 65CG-036806 - Drug Profile 66Drug to Inhibit BTK for Undisclosed Indications - Drug Profile 67DTRMWXHS-12 - Drug Profile 68EBI-1266 - Drug Profile 69EBI-1367 - Drug Profile 70HCl-1401 - Drug Profile 71HCl-1684 - Drug Profile 72HM-71224 - Drug Profile 73ibrutinib - Drug Profile 74M-2951 - Drug Profile 97M-7583 - Drug Profile 98ONO-4059 - Drug Profile 99PLS-123 - Drug Profile 101PNQ-154 - Drug Profile 102PNQ-849 - Drug Profile 103PRN-1008 - Drug Profile 104PRN-473 - Drug Profile 106RDX-002 - Drug Profile 107RG-7845 - Drug Profile 108Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile 109Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders and Rheumatoid Arthritis - Drug Profile 110Small Molecule to Inhibit BTK for Immunology - Drug Profile 111Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile 112Small Molecule to Inhibit BTK for Oncology - Drug Profile 113Small Molecule to Target BTK for Immunology - Drug Profile 114Small Molecules to Inhibit BTK for Oncology - Drug Profile 115Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile 116SNS-062 - Drug Profile 118spebrutinib besylate - Drug Profile 120TAK-020 - Drug Profile 122X-022 - Drug Profile 123Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Dormant Projects 124Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Discontinued Products 127Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine

Kinase or BTK or EC 2.7.10.2) - Featured News & Press Releases 128Appendix 140Methodology 140Coverage  
140Secondary Research 140Primary Research 140Expert Panel Validation 140Contact Us 140Disclaimer 141

# How to Buy...

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016  
[Published by Global Markets Direct]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/20637>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$3080** | Single User Price
- \$6160** | Site License Price
- \$9240** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.